Pathogenesis of triple-negative breast cancer
F Derakhshan, JS Reis-Filho - Annual Review of Pathology …, 2022 - annualreviews.org
Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …
fundamentally different diseases with different histologic, genomic, and immunologic …
Synthetic lethality in cancer therapeutics: the next generation
Synthetic lethality (SL) provides a conceptual framework for tackling targets that are not
classically “druggable,” including loss-of-function mutations in tumor suppressor genes …
classically “druggable,” including loss-of-function mutations in tumor suppressor genes …
Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the …
Purpose: Genomic alterations in DNA damage repair (DDR) genes other than BRCA may
confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate …
confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate …
Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline
NM Tung, JC Boughey, LJ Pierce… - Journal of clinical …, 2020 - ascopubs.org
PURPOSE To develop recommendations for management of patients with breast cancer
(BC) with germline mutations in BC susceptibility genes. METHODS The American Society …
(BC) with germline mutations in BC susceptibility genes. METHODS The American Society …
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Predictive biomarkers of response are essential to effectively guide targeted cancer
treatment. Ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) have been shown …
treatment. Ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) have been shown …
Advancing personalized medicine through the application of whole exome sequencing and big data analytics
There is a growing attention toward personalized medicine. This is led by a fundamental
shift from the 'one size fits all'paradigm for treatment of patients with conditions or …
shift from the 'one size fits all'paradigm for treatment of patients with conditions or …
Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma
Background and Aims Homologous recombination deficiency (HRD) in pancreatic ductal
adenocarcinoma (PDAC), remains poorly defined beyond germline (g) alterations in …
adenocarcinoma (PDAC), remains poorly defined beyond germline (g) alterations in …
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
The homologous recombination deficiency (HRD) score integrates three DNA-based
measures of genomic instability, and has been understudied in prostate cancer. Given the …
measures of genomic instability, and has been understudied in prostate cancer. Given the …
Hereditary breast cancer: syndromes, tumour pathology and molecular testing
A Sokolova, KJ Johnstone, AE McCart Reed… - …, 2023 - Wiley Online Library
Hereditary factors account for a significant proportion of breast cancer risk. Approximately
20% of hereditary breast cancers are attributable to pathogenic variants in the highly …
20% of hereditary breast cancers are attributable to pathogenic variants in the highly …
Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations
Background Poly ADP-ribose polymerase (PARP) inhibitors, such as olaparib, are being
explored as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) …
explored as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) …